Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Neuroblastoma is a common childhood neuroendocrine tumor with high malignancy and recurrence rates.
• The glycogen synthase kinase-3 (GSK-3) pathway is a potential therapeutic target in neuroendocrine tumors.
• The specific GSK-3 isoform critical for neuroblastoma growth inhibition remains unclear.

Purpose of the Study:

• To investigate the effect of the GSK-3 inhibitor AR-A014418 on different GSK-3 isoforms in neuroblastoma.
• To determine if AR-A014418 can inhibit neuroblastoma cell growth and affect neuroendocrine markers.

Main Methods:

• NGP and SH-5Y-SY neuroblastoma cells were treated with varying concentrations of AR-A014418.
• Cell viability was assessed using MTT assay.
• Expression of neuroendocrine markers (CgA, ASCL1), GSK-3 isoforms, and apoptotic markers was analyzed via western blot.

Main Results:

• AR-A014418 treatment led to a significant reduction in neuroblastoma cell growth across all tested doses and time points (P<0.001).
• A notable decrease in tumor markers ASCL1 and CgA expression was observed, correlating with growth inhibition.
• Treatment reduced GSK-3α phosphorylation at Tyr279 more than GSK-3β phosphorylation at Tyr216.

Conclusions:

• AR-A014418 attenuates neuroblastoma growth by promoting apoptosis.
• GSK-3α inhibition appears to be the primary mechanism for downregulating neuroendocrine tumor markers and inhibiting growth in neuroblastoma.
• Further research is warranted to fully elucidate the mechanisms of GSK-3α inhibition in neuroblastoma treatment.